Cartilage-supporting research peptide (Cartalax / AEDL)
A tiny lab-made peptide studied for slowing cartilage aging and joint cell decline; experimental, not an approved drug.
- Class
- Bioregulatory tripeptide (Khavinson system)
- Status
- Not approved by any major reference regulatory authority
- Best-supported effect
- Increased proliferation markers, MMP-9 inhibition, and reduced senescence indicators in chondrocyte cell cultures (in vitro, Khavinson group only)
- Main caveat
- Entire evidence base originates from a single research orbit with no independent Western replication; Russian clinical reports are not PubMed-indexed and do not meet Western trial-methodology standards; no controlled human efficacy data identified
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Bioregulatory tripeptide (Khavinson system)
Evidence tier: In vitro / assay evidence
Status: Not approved by FDA, EMA, MHRA, Health Canada, or TGA; no approved therapeutic status identified in any major reference regulatory jurisdiction
Best-supported effect: Increased proliferation markers, MMP-9 inhibition, and reduced senescence indicators in chondrocyte cell cultures (in vitro, Khavinson group only)
Main caveat: Entire evidence base originates from a single research orbit with no independent Western replication; Russian clinical reports are not PubMed-indexed and do not meet Western trial-methodology standards; no controlled human efficacy data identified
What this is
Cartalax is a synthetic tripeptide consisting of alanine, glutamic acid, and aspartic acid (Ala-Glu-Asp, also designated AED), developed within Vladimir Khavinson's bioregulator peptide program at the St. Petersburg Institute of Bioregulation and Gerontology. Its amino acid sequence corresponds to a motif identified in the alpha-1 chain of type XI collagen, a structural protein involved in cartilage integrity, which forms the structural rationale for its proposed cartilage-maintenance role. It is classified as a Cytogen — a laboratory-synthesized short peptide designed to mirror regulatory effects proposed for peptides naturally present in cartilage tissue. The natural-extract counterpart to Cartalax within the Khavinson system is Sigumir, a peptide complex derived from animal cartilage and bone tissue. The published research base for Cartalax specifically consists primarily of in vitro chondrocyte studies from the Khavinson group; independent Western replication of these findings has not occurred, and there are no registered or completed controlled human trials for this peptide in international databases.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | None | No completed controlled human trial data identified, a non-PubMed-indexed Russian clinical report is mentioned but does not meet criteria for human-tier evidence |
| Animal | None | No animal in vivo study data identified |
| In vitro | Moderate (single-orbit) | Increased cartilage area index (18–38%), MMP-9 inhibition, SIRT1 and SIRT6 upregulation, reduced p53 and caspase-3 activity, and reduced senescence markers (p16, p21) in chondrocyte cultures — all from the Khavinson research group; independent replication not identified |
| Computational | None | No computational or docking data identified |
| Mechanism | Plausible, unvalidated | Proposed direct DNA interaction and cartilage-gene reactivation via Ala-Glu-Asp sequence homology to type XI collagen motif; core mechanism claim has not been independently validated |
> The entirety of the in vitro evidence base originates from a single research orbit (Khavinson group, St. Petersburg). Independent Western laboratory replication of the chondrocyte findings has not been identified. The broader Khavinson program's claim of direct DNA interaction by tripeptides is contested in the wider scientific community. Source references include reviews of the broader Khavinson short-peptide program rather than Cartalax-specific controlled studies.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Increases proliferation markers and reduces senescence indicators in chondrocyte cultures | Supported (in vitro) | In vitro | Medium — single research orbit; no independent replication |
| MMP-9 inhibition in cartilage cell assays | Supported (in vitro) | In vitro | Medium — single research orbit; no independent replication |
| Cartilage protection or joint health benefit in humans | Not established | Human | Low — Russian clinical report not PubMed-indexed; no controlled human trial data in source |
| Osteoarthritis or degenerative joint disease treatment efficacy | Not established | Human | Low — no blinded RCT identified; Russian clinical reports not indexed or replicated |
| Sequence homology to type XI collagen proves clinical cartilage benefit | Not established | In vitro | High — sequence homology is a hypothesis-generating observation, not a demonstration of clinical effect; many short peptide sequences match structural protein motifs without recapitulating function |
| Direct DNA interaction by the tripeptide as a validated mechanism | Weak | In vitro | Low — proposed mechanism is contested; direct DNA interaction by a tripeptide of this size has not been independently validated |
Assay conditions
This section reports concentrations or conditions used in the in vitro assays described in available literature. It does not establish animal or human exposure.
| Context | System | Assay condition | Timepoint | Endpoint | Limitation |
|---|---|---|---|---|---|
| In vitro chondrocyte assay | Chondrocyte cultures (young and old specimens) | Ala-Glu-Asp peptide addition; concentration not individually extracted | Not individually extracted | Cartilage area index (18–38% increase reported), MMP-9 inhibition, SIRT1/SIRT6 upregulation, p53 and caspase-3 reduction, senescence markers (p16, p21) | Khavinson group only; no independent replication; exact assay concentration and protocol details not separately extracted from source |
| In vitro stem cell / fibroblast culture | Human mesenchymal stem cells; fibroblast cultures | Short peptide addition (Khavinson program, broader context) | Not individually extracted | Gene expression modulation, proliferation markers (Ki-67) | Evidence from broader Khavinson program, not Cartalax-specific; listed PMIDs are reviews and preclinical reports from the broader program |
Assay limitations
- All identified in vitro data originates from the Khavinson research group; no independent Western laboratory replication of Cartalax-specific assay findings has been identified.
- Exact assay concentrations, protocols, and controls are not individually extracted from the available literature.
- In vitro chondrocyte activity does not establish systemic tolerability, pharmacokinetics, or therapeutic effect in intact organisms.
- The proposed mechanism — direct DNA interaction by a small tripeptide — is contested in the broader scientific community and has not been independently validated.
- The sequence PMIDs identified reference reviews and broad Khavinson program preclinical work, not Cartalax-specific controlled studies.
- No animal toxicology or human safety data are identified.
Regulatory status
No approved therapeutic status identified for any major reference regulatory jurisdiction.
| Region / body | Status | Notes |
|---|---|---|
| US (FDA) | Not approved | Not approved for any indication; not recognized as a dietary supplement ingredient; not on the FDA 503A bulk-substance eligible compounding list; Per available sources, injectable forms sold primarily through research-chemical suppliers |
| EU (EMA) | Not approved | Per available sources, no EMA approval; independently not verified in this card |
| UK (MHRA) | Not approved | Per available sources, no MHRA approval |
| Canada (Health Canada) | Not approved | Per available sources, no Health Canada approval |
| Russia / CIS | Not a registered pharmaceutical | Source describes Russian Khavinson-affiliated capsule and sublingual products marketed as dietary peptide complexes, not as registered pharmaceuticals; this regulatory category carries lower evidence requirements than prescription-medicine approval and is not equivalent to FDA or EMA status |
| WADA | Unclear; likely S0 catch-all applies to injectable forms | Cartalax is not specifically named on the WADA Prohibited List; Per available sources, that as an unapproved substance, the WADA S0 catch-all category likely applies to injectable forms; status not independently refreshed in this card |
Mechanism
Cartalax (Ala-Glu-Asp) is proposed to penetrate cell membranes by virtue of its small molecular size (approximately 333 Da) and to interact directly with DNA regulatory regions in chondrocytes and fibroblasts. The structural rationale rests on the observation that the Ala-Glu-Asp sequence corresponds to a motif in the alpha-1 chain of type XI collagen, a protein integral to cartilage architecture.
In vitro studies from the Khavinson group report that exposure to Cartalax is associated with upregulation of Ki-67 (a proliferation marker), increased SIRT1 and SIRT6 expression (longevity-associated deacetylases), reduced p53 and caspase-3 activity (pro-apoptotic signaling components), and inhibition of MMP-9 synthesis (a matrix metalloproteinase involved in extracellular matrix degradation that increases with cellular aging). Cartilage area index increases of 18–38% have been reported in chondrocyte cultures from both young and older specimens.
Published research also describes proposed modulation of Wnt/beta-catenin signaling and stimulation of type II collagen and aggrecan synthesis.
Mechanism limitations: The core claim — that a tripeptide directly interacts with DNA to reactivate cartilage-maintenance gene programs — is contested in the broader scientific community and has not been independently validated outside the Khavinson research orbit. Sequence homology between Ala-Glu-Asp and a type XI collagen motif is a hypothesis-generating observation; it does not demonstrate that the tripeptide retains or recapitulates the larger protein's structural or regulatory function. Target confidence is classified as inferred from source context, not experimentally verified by an independent program.
Chemistry
| Field | Value |
|---|---|
| Amino acid sequence | Ala-Glu-Asp (AED) |
| Length | 3 amino acids |
| Topology | Linear |
| Molecular weight | Approximately 333 Da (per available sources; not independently verified in this card) |
| Modifications | None reported in source |
| CAS | Not individually extracted from source |
| Salt form | Not individually extracted from source |
| Sequence confidence | Needs review — sequence is per available sources from the Khavinson program; independent primary sequence verification not identified |
> Note: Published research also lists "T-31" and "Cartilage Bioregulator" as aliases alongside "AED" and "Ala-Glu-Asp." Relationship between these designations and any independent chemical registry entry is not confirmed in the available literature.
Open questions
- Independent replication: In vitro chondrocyte findings have not been reproduced by laboratories outside the Khavinson research orbit. Replication under blinded and controlled conditions would be the minimum threshold for assessing whether the reported effects are reproducible.
- Controlled human evidence: No blinded randomized controlled trial in osteoarthritis, osteochondrosis, or any joint-health endpoint has been identified for Cartalax. The Russian clinical report described in available literature is not indexed in PubMed and does not meet Western trial-methodology standards.
- Pharmacokinetics: Absorption (particularly oral and sublingual bioavailability of the intact tripeptide), distribution to cartilage tissue, and clearance have not been characterized in any independently published study. The Khavinson group's claims of intact-peptide absorption are not confirmed by independent pharmacokinetic data.
- Mechanism validation: Direct DNA interaction by a tripeptide and the resulting gene-reactivation claim have not been independently validated. This is the foundational mechanistic claim of the Khavinson short-peptide program and would require independent confirmation before the mechanism can be treated as established.
- Long-term safety: No long-term safety data from controlled studies have been identified. The proposed proliferation-stimulating effect on chondrocytes raises a theoretical concern regarding tumor-promotion risk in the context of subclinical malignancy that has not been adequately addressed in the available source material.
- Sequence registry confirmation: The relationship between the Ala-Glu-Asp tripeptide and any independently registered chemical identifier (CAS, ChemSpider, PubChem) is not confirmed in the available literature.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does AEDL make cartilage cells appear younger because it stops the enzyme that generates fragments that trigger aging, rather than directly reversing the aging process?
If cartilage aging is prevented indirectly through matrix protection, this finding would clarify whether AEDL-like peptides belong in the anti-aging pipeline or the anti-inflammatory one, helping doctors and drug developers target treatments more precisely for arthritis patients.
Could AEDL work in spinal disc cells the same way it appears to work in joint cells, since both use the same structural protein?
If AEDL can protect intervertebral discs, it could potentially become a treatment for disc degeneration, one of the most common causes of chronic back pain worldwide, for which no proven biological treatment currently exists.
Could a chemically reinforced version of AEDL be designed to pass through the stomach intact and still protect cartilage?
If a stable version of AEDL can be made, it would be the first orally available cartilage-protective peptide with a defined mechanism, offering millions of arthritis patients a potential new treatment they can take as a pill.
▸3-letter notation
▸citationbibtex
@peptide{pep10936,
sequence = {AEDL},
target = {},
author = {peptidemodel},
year = {2026},
status = {designed}
}